Table 1.

Roles of “writers”, “erasers”, and “readers” of m6A and 6mA in different tumors

	Target	Class	Name	Tumor	Function	Reference
RNA	mRNA	“Writers”	METTL	Glioma	Maintain stem cell pluripotency	67
					Inhibit stem cell pluripotency	66
				AML	Maintain stem cell pluripotency	37
					Promote tumor progression	54
				CRC	Promote tumor progression	56
				Bladder cancer	Promote tumor progression	39
					Promote tumorigenesis	58
				HCC	Promote tumor progression	57
					Epithelial-mesenchymal transition	51
					DNA damage response	53
				Renal cancer	Suppress tumor progression	65
			METTL14	AML	Maintain stem cell pluripotency	38
				Glioma	Inhibit stem cell pluripotency	66
				Renal cancer	Promote tumor progression	55
					Epithelial-mesenchymal transition, angiogenesis	52
				Endometrial cancer	Suppress tumor tumorigenicity	64
		“Erasers”	FTO	AML	Maintain stem cell pluripotency	40
					Promote tumor progression	73
				Melanoma	Promote tumor progression	71
				Breast cancer	Promote tumor progression	72
				Glioma	Maintain stem cell pluripotency	66
			ALKBH5	Glioma	Promote tumorigenesis	74
		“Readers”	YTHDF2	AML	Maintain stem cell pluripotency	42
				Liver cancer	Promote tumor progression	57
			YTHDF1	Melanoma	Suppress antitumor immunity	87
			IGFBP1	Ovarian cancer; liver cancer; lung cancer	Promote tumor progression	86
	Non-coding RNA	“Writer”	METTL3	Bladder cancer;	Promote tumor progression	59
				Gastric cancer	Promote tumor progression	63
		“Eraser”	ALKBH5	Gastric cancer	Promote tumor progression	75
DNA	DNA	“Writer”	N6AMT1	Gastric cancer; liver cancer	Inhibit tumorigenesis and metastasis	29
		“Eraser”	ALKBH1	Glioblastoma	Maintain cell viability and stemness properties	30
				Gastric cancer; liver cancer	Promote tumorigenesis and metastasis	29

AML, acute myelocytic leukemia; CRC, colorectal carcinoma; HCC, hepatocellular carcinoma.